Why the study?
Does massively parallel sequencing improve mutation screening compared to Sanger-based sequencing in patients with inherited cardiac conditions?
Population
People between the ages of 1–40 years with sudden cardiac death or inherited cardiac conditions and their…
Comparison
Massively parallel sequencing (MPS) vs Sanger-based sequencing
Design
Review
Authors
Loading...
May support broader genetic testing in inherited cardiac conditions; leaves open prospective validation of diagnostic performance.
Does massively parallel sequencing improve mutation screening compared to Sanger-based sequencing in patients with inherited cardiac conditions?
Massively parallel sequencing provides a more efficient and cost-effective approach than Sanger sequencing for genetic screening of inherited cardiac conditions.
Leong et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: